Bioenvision to Present at the 24th Annual JPMorgan Healthcare Conference
05 January 2006 - 11:00PM
Business Wire
Bioenvision, Inc. (Nasdaq: BIVN) announced today that Dr.
Christopher B. Wood, Chairman and Chief Executive Officer of the
Company, will present at the 24th Annual JPMorgan Healthcare
Conference, Tuesday, January 10, 2006, at 11:30 am PST in San
Francisco. An audio webcast of the presentation will be available
to all interested parties at Bioenvision's website
(www.bioenvision.com) or directly accessed by the following link:
http://equityconferences.jpmorgan.com. About clofarabine
Clofarabine is a next generation purine nucleoside analog. This
class of drugs inhibits DNA production necessary for cancer cell
growth. Bioenvision and Genzyme Corporation (Nasdaq: GENZ) are
co-developing clofarabine. Bioenvision holds an exclusive worldwide
license for clofarabine (outside Japan and Southeast Asia).
Bioenvision granted an exclusive sublicense to Genzyme to develop
and commercialize clofarabine for cancer indications in the US and
Canada. Bioenvision holds an exclusive license in the US and Canada
for all non-cancer indications and an exclusive, irrevocable option
to develop and market clofarabine for all human applications in
Japan and Southeast Asia. Bioenvision originally obtained
clofarabine development and commercialization rights under patents
held by Southern Research Institute. Clofarabine has been granted
orphan drug designation for the treatment of adult and pediatric
ALL and AML in the U.S. and Europe. In the U.S., orphan drug status
extends market exclusivity for seven years. The FDA also recently
granted an additional six months market exclusivity to clofarabine
under the Best Pharmaceuticals for Children Act. In Europe, the
designation provides marketing exclusivity for 10 years following
Market Authorization. In December 2004, FDA approved the use of
clofarabine for treatment of pediatric patients 1 to 21 years old
with relapsed or refractory ALL after at least two prior regimens.
In Europe, Bioenvision filed a marketing authorization application
(MAA) for clofarabine via the Centralized Procedure in July 2004.
About Bioenvision Bioenvision's primary focus is the acquisition,
development, distribution and marketing of compounds and
technologies for the treatment of cancer. Bioenvision has a broad
pipeline of products for the treatment of cancer, including:
clofarabine (in co-development with Genzyme Corporation),
Modrenal(R) (for which Bioenvision has obtained regulatory approval
for marketing in the United Kingdom for the treatment of
post-menopausal breast cancer following relapse to initial hormone
therapy), and other products in clinical trials. Bioenvision is
also developing anti-infective technologies, including the OLIGON
technology; an advanced biomaterial that has been incorporated into
various FDA approved medical devices. For more information on
Bioenvision please visit our Web site at www.bioenvision.com.
Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements.
Specifically, factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to: risks associated with
preclinical and clinical developments in the biopharmaceutical
industry in general and in Bioenvision's compounds under
development in particular; the potential failure of Bioenvision's
compounds under development to prove safe and effective for
treatment of disease; uncertainties inherent in the early stage of
Bioenvision's compounds under development; failure to successfully
implement or complete clinical trials; failure to receive marketing
clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure
or projections; the development of competing products;
uncertainties related to Bioenvision's dependence on third parties
and partners; and those risks described in Bioenvision's filings
with the SEC. Bioenvision disclaims any obligation to update these
forward-looking statements.
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Bioenvision (MM) (NASDAQ): 0 recent articles
More Bioenvision, Inc. News Articles